Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Franchi

Showing results (101-110 of 147) with videos related to

Pageof 15
Sort By:
JACC. Cardiovascular Interventions|August 5, 2019
Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With MorphineFrancesco Franchi, Fabiana Rollini, Yongwhi Park, et al.
Vascular Pharmacology|January 31, 2023
Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromesWilliam A E Parker, Dominick J Angiolillo, Fabiana Rollini, et al.
European Heart Journal|February 6, 2016
A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized studyFabiana Rollini, Francesco Franchi, Jung Rae Cho, et al.
JACC. Advances|February 4, 2026
Impact of Area-Level Socioeconomic Deprivation on Post-PCI Outcomes Stratified by P2Y<sub>12</sub> Inhibitor TherapyJean G Malavé, Cameron D Thomas, Francesco Franchi, et al.
JACC. Cardiovascular Interventions|May 26, 2026
Oral Anticoagulation With or Without Antiplatelet Therapy in Chronic Coronary Syndrome: A Meta-Analysis of Randomized TrialsMattia Galli, Mattia Vinciguerra, Claudio Laudani, et al.
Thrombosis and Haemostasis|May 24, 2023
Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) StudyLuis Ortega-Paz, Francesco Franchi, Fabiana Rollini, et al.
Pharmacogenomics and Personalized Medicine|August 9, 2020
Development of Customizable Implementation Guides to Support Clinical Adoption of Pharmacogenomics: Experiences of the Implementing GeNomics In pracTicE (IGNITE) NetworkBenjamin Q Duong, Meghan J Arwood, J Kevin Hicks, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 11, 2021
Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery diseaseFrancesco Franchi, Fabiana Rollini, Latonya Been, et al.
JACC. Cardiovascular Interventions|November 1, 2022
Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor: The Switching Antiplatelet (SWAP)-5 StudyFrancesco Franchi, Luis Ortega-Paz, Fabiana Rollini, et al.
Journal of Cardiovascular Translational Research|January 8, 2014
Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic studyFabiana Rollini, Francesco Franchi, Jung Rae Cho, et al.
Pageof 15

Showing results (101-110 of 147) with videos related to

Sort By:
Pageof 15
JACC. Cardiovascular Interventions|August 5, 2019
Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With MorphineFrancesco Franchi, Fabiana Rollini, Yongwhi Park, et al.
Vascular Pharmacology|January 31, 2023
Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromesWilliam A E Parker, Dominick J Angiolillo, Fabiana Rollini, et al.
European Heart Journal|February 6, 2016
A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized studyFabiana Rollini, Francesco Franchi, Jung Rae Cho, et al.
JACC. Advances|February 4, 2026
Impact of Area-Level Socioeconomic Deprivation on Post-PCI Outcomes Stratified by P2Y<sub>12</sub> Inhibitor TherapyJean G Malavé, Cameron D Thomas, Francesco Franchi, et al.
JACC. Cardiovascular Interventions|May 26, 2026
Oral Anticoagulation With or Without Antiplatelet Therapy in Chronic Coronary Syndrome: A Meta-Analysis of Randomized TrialsMattia Galli, Mattia Vinciguerra, Claudio Laudani, et al.
Thrombosis and Haemostasis|May 24, 2023
Switching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) StudyLuis Ortega-Paz, Francesco Franchi, Fabiana Rollini, et al.
Pharmacogenomics and Personalized Medicine|August 9, 2020
Development of Customizable Implementation Guides to Support Clinical Adoption of Pharmacogenomics: Experiences of the Implementing GeNomics In pracTicE (IGNITE) NetworkBenjamin Q Duong, Meghan J Arwood, J Kevin Hicks, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 11, 2021
Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery diseaseFrancesco Franchi, Fabiana Rollini, Latonya Been, et al.
JACC. Cardiovascular Interventions|November 1, 2022
Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor: The Switching Antiplatelet (SWAP)-5 StudyFrancesco Franchi, Luis Ortega-Paz, Fabiana Rollini, et al.
Journal of Cardiovascular Translational Research|January 8, 2014
Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic studyFabiana Rollini, Francesco Franchi, Jung Rae Cho, et al.
Pageof 15